ERBB2 and breast carcinoma: On the other hand, similar to ~30% of breast cancers, advanced PyMT tumors express high levels of ErbB2 [3] Indeed, PyMT tumors respond to the EGFR/ErbB2 tyrosine kinase inhibitor lapatinib [66].